Allarity Therapeutics, Inc. financial data

Symbol
ALLR on Nasdaq
Industry
Pharmaceutical Preparations
Location
24 School St., 2 Nd Floor, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 91.5 % +193%
Debt-to-equity 219 %
Return On Equity -319 % -145%
Return On Assets -100 % -4.82%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.43M shares -2.74%
Common Stock, Shares, Outstanding 2.76M shares -34.1%
Entity Public Float 3.32M USD -68.6%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 1.58M shares +38100%
Weighted Average Number of Shares Outstanding, Diluted 15M shares +80342%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.87M USD +26.8%
General and Administrative Expense 8.23M USD -17.8%
Operating Income (Loss) -24.8M USD -30.5%
Nonoperating Income (Expense) 5.72M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -19.1M USD -169%
Income Tax Expense (Benefit) -377K USD
Net Income (Loss) Attributable to Parent -18.8M USD -44.3%
Earnings Per Share, Basic 8.19K USD/shares +99.4%
Earnings Per Share, Diluted 6.85K USD/shares +100%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 19.2M USD +4479%
Other Assets, Current 100K USD -90.3%
Assets, Current 20.4M USD +364%
Property, Plant and Equipment, Net 12K USD -58.6%
Operating Lease, Right-of-Use Asset 6K USD -93%
Intangible Assets, Net (Excluding Goodwill) 0 USD
Assets 20.4M USD +46.9%
Accounts Payable, Current 4.69M USD -26.1%
Accrued Liabilities, Current 1.32M USD -11%
Liabilities, Current 7.41M USD -52.9%
Deferred Income Tax Liabilities, Net 0 USD -100%
Liabilities 7.41M USD -57%
Accumulated Other Comprehensive Income (Loss), Net of Tax -693K USD +8.58%
Retained Earnings (Accumulated Deficit) -112M USD -20.3%
Stockholders' Equity Attributable to Parent 13M USD
Liabilities and Equity 20.4M USD +46.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.49M USD +53.5%
Net Cash Provided by (Used in) Financing Activities 1.38M USD +19.2%
Net Cash Provided by (Used in) Investing Activities 809K USD
Common Stock, Shares Authorized 250M shares -66.7%
Common Stock, Shares, Issued 2.76M shares -34.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.04M USD +58.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 18.5M USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 9K USD -30.8%
Deferred Tax Assets, Valuation Allowance 16.8M USD +26.1%
Deferred Tax Assets, Gross 16.3M USD +26.1%
Operating Lease, Liability 8K USD -92.5%
Depreciation 23K USD -58.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -18.7M USD -57.3%
Operating Lease, Liability, Current 8K USD -91.8%
Deferred Income Tax Expense (Benefit) -14K USD
Deferred Tax Assets, Operating Loss Carryforwards 17M USD +30.6%
Preferred Stock, Shares Issued 0 shares -100%
Additional Paid in Capital 125M USD +41.7%
Preferred Stock, Shares Outstanding 0 shares -100%
Depreciation, Depletion and Amortization 23K USD -58.9%
Share-based Payment Arrangement, Expense 17K USD -90.6%
Interest Expense 508K USD +84.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%